CaliPharms (OTCPK:KGET) - Stock Price, News & Analysis

KGET Stock Overview

Engages in the medicinal Cannabis Industry in the United States. More details

KGET fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

Does not have a meaningful market cap ($14K)

Shares are highly illiquid

CaliPharms, Inc. Competitors

EESTech

OTCPK:EESH

US$118.6k

voxeljet

OTCPK:VJTT.Y

US$456.7k

Future Mobility Solutions

OTCPK:SLFF.F

US$28.3k

Molekule Group

OTCPK:MKUL.Q

US$15.3k

Price History & Performance

Summary of all time highs, changes and price drops for CaliPharms
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
11 Month Change	-97.50%
3 Month Change	0%
1 Year Change	n/a
33 Year Change	-90.00%
5 Year Change	-99.00%
Change since IPO	-99.98%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	KGET	US Machinery	US Market
7D	0%	3.9%	1.6%
1Y	n/a	32.4%	32.3%

Return vs Industry: Insufficient data to determine how KGET performed against the US Machinery industry.

Return vs Market: Insufficient data to determine how KGET performed against the US Market.

Price Volatility

Is KGET's price volatile compared to industry and market?
KGET volatility
KGET Average Weekly Movement	n/a
Machinery Industry Average Movement	5.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: KGET's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine KGET's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Eric Watson	n/a

CaliPharms, Inc. engages in the medicinal Cannabis Industry in the United States. It focuses on the THC and CBD beverage industry. The company was formerly known as Kleangas Energy Technologies, Inc. and changed its name to CaliPharms, Inc. in January, 2017.

CaliPharms, Inc. Fundamentals Summary

How do CaliPharms's earnings and revenue compare to its market cap?
KGET fundamental statistics
Market cap	US$13.88k
Earnings (TTM)	-US$6.31m
Revenue (TTM)	US$112.47k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is KGET overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KGET income statement (TTM)
Revenue	US$112.47k
Cost of Revenue	US$143.03k
Gross Profit	-US$30.57k
Other Expenses	US$6.28m
Earnings	-US$6.31m

Last Reported Earnings

Sep 30, 2014

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did KGET perform over the long term?

See historical performance and comparison